These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 15756684)

  • 1. Cytotoxic effects of gammadelta T cells expanded ex vivo by a third generation bisphosphonate for cancer immunotherapy.
    Sato K; Kimura S; Segawa H; Yokota A; Matsumoto S; Kuroda J; Nogawa M; Yuasa T; Kiyono Y; Wada H; Maekawa T
    Int J Cancer; 2005 Aug; 116(1):94-9. PubMed ID: 15756684
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytotoxic human peripheral blood-derived γδT cells kill glioblastoma cell lines: implications for cell-based immunotherapy for patients with glioblastoma.
    Nakazawa T; Nakamura M; Park YS; Motoyama Y; Hironaka Y; Nishimura F; Nakagawa I; Yamada S; Matsuda R; Tamura K; Sugimoto T; Takeshima Y; Marutani A; Tsujimura T; Ouji N; Ouji Y; Yoshikawa M; Nakase H
    J Neurooncol; 2014 Jan; 116(1):31-9. PubMed ID: 24062140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effect of zoledronate on the cytotoxicity of γδ T cells from PBMCs of osteosarcoma patients against osteosarcoma].
    Li Z; Tang J; Sun L; Ye Z
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2013 Jan; 29(1):6-9. PubMed ID: 23294710
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Isopentenyl pyrophosphate secreted from Zoledronate-stimulated myeloma cells, activates the chemotaxis of γδT cells.
    Ashihara E; Munaka T; Kimura S; Nakagawa S; Nakagawa Y; Kanai M; Hirai H; Abe H; Miida T; Yamato S; Shoji S; Maekawa T
    Biochem Biophys Res Commun; 2015 Aug; 463(4):650-5. PubMed ID: 26047704
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatocellular carcinoma cell sensitivity to Vγ9Vδ2 T lymphocyte-mediated killing is increased by zoledronate.
    Sugai S; Yoshikawa T; Iwama T; Tsuchiya N; Ueda N; Fujinami N; Shimomura M; Zhang R; Kaneko S; Uemura Y; Nakatsura T
    Int J Oncol; 2016 May; 48(5):1794-804. PubMed ID: 26936487
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vγ9Vδ2 T cells and zoledronate mediate antitumor activity in an orthotopic mouse model of human chondrosarcoma.
    Sun L; Li Y; Jiang Z; Zhang J; Li H; Li B; Ye Z
    Tumour Biol; 2016 Jun; 37(6):7333-44. PubMed ID: 26676633
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction of gamma delta T cells using zoledronate plus interleukin-2 in patients with metastatic cancer.
    Nagamine I; Yamaguchi Y; Ohara M; Ikeda T; Okada M
    Hiroshima J Med Sci; 2009 Mar; 58(1):37-44. PubMed ID: 19400555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravesical administration of gammadelta T cells successfully prevents the growth of bladder cancer in the murine model.
    Yuasa T; Sato K; Ashihara E; Takeuchi M; Maita S; Tsuchiya N; Habuchi T; Maekawa T; Kimura S
    Cancer Immunol Immunother; 2009 Apr; 58(4):493-502. PubMed ID: 18682944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Type I IFN-mediated enhancement of anti-leukemic cytotoxicity of gammadelta T cells expanded from peripheral blood cells by stimulation with zoledronate.
    Watanabe N; Narita M; Yokoyama A; Sekiguchi A; Saito A; Tochiki N; Furukawa T; Toba K; Aizawa Y; Takahashi M
    Cytotherapy; 2006; 8(2):118-29. PubMed ID: 16698685
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Zoledronate facilitates large-scale ex vivo expansion of functional gammadelta T cells from cancer patients for use in adoptive immunotherapy.
    Kondo M; Sakuta K; Noguchi A; Ariyoshi N; Sato K; Sato S; Sato K; Hosoi A; Nakajima J; Yoshida Y; Shiraishi K; Nakagawa K; Kakimi K
    Cytotherapy; 2008; 10(8):842-56. PubMed ID: 19016372
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of IL-18 on expansion of gammadelta T cells stimulated by zoledronate and IL-2.
    Li W; Kubo S; Okuda A; Yamamoto H; Ueda H; Tanaka T; Nakamura H; Yamanishi H; Terada N; Okamura H
    J Immunother; 2010 Apr; 33(3):287-96. PubMed ID: 20445349
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Cancer immunotherapy using gammadelta T cells ex vivo expanded by bisphosphonate].
    Kimura S
    Clin Calcium; 2008 Apr; 18(4):499-505. PubMed ID: 18379032
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Osteosarcoma cell line growth inhibition by zoledronate-stimulated effector cells.
    Muraro M; Mereuta OM; Carraro F; Madon E; Fagioli F
    Cell Immunol; 2007 Oct; 249(2):63-72. PubMed ID: 18163982
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Zoledronic acid and interleukin-2 treatment improves immunocompetence in HIV-infected persons by activating Vgamma9Vdelta2 T cells.
    Poccia F; Gioia C; Martini F; Sacchi A; Piacentini P; Tempestilli M; Agrati C; Amendola A; Abdeddaim A; Vlassi C; Malkovsky M; D'Offizi G
    AIDS; 2009 Mar; 23(5):555-65. PubMed ID: 19238075
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Amplification of γδ T cells in PBMCs of healthy donors and osteosarcoma patients stimulated by zoledronate].
    Li ZX; Sun LL; Cheng RL; Sun ZW; Ye ZM
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2012 Aug; 28(8):822-4. PubMed ID: 22863589
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of γδ T cell responses and farnesyl diphosphate synthase inhibition in tumor cells pretreated with zoledronic acid.
    Idrees AS; Sugie T; Inoue C; Murata-Hirai K; Okamura H; Morita CT; Minato N; Toi M; Tanaka Y
    Cancer Sci; 2013 May; 104(5):536-42. PubMed ID: 23387443
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effector gammadelta T cells and tumor cells as immune targets of zoledronic acid in multiple myeloma.
    Mariani S; Muraro M; Pantaleoni F; Fiore F; Nuschak B; Peola S; Foglietta M; Palumbo A; Coscia M; Castella B; Bruno B; Bertieri R; Boano L; Boccadoro M; Massaia M
    Leukemia; 2005 Apr; 19(4):664-70. PubMed ID: 15744346
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adoptive transfer of ex vivo expanded Vγ9Vδ2 T cells in combination with zoledronic acid inhibits cancer growth and limits osteolysis in a murine model of osteolytic breast cancer.
    Zysk A; DeNichilo MO; Panagopoulos V; Zinonos I; Liapis V; Hay S; Ingman W; Ponomarev V; Atkins G; Findlay D; Zannettino A; Evdokiou A
    Cancer Lett; 2017 Feb; 386():141-150. PubMed ID: 27865798
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nano-technology based carriers for nitrogen-containing bisphosphonates delivery as sensitisers of γδ T cells for anticancer immunotherapy.
    Hodgins NO; Wang JT; Al-Jamal KT
    Adv Drug Deliv Rev; 2017 May; 114():143-160. PubMed ID: 28694026
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High phosphoantigen levels in bisphosphonate-treated human breast tumors promote Vgamma9Vdelta2 T-cell chemotaxis and cytotoxicity in vivo.
    Benzaïd I; Mönkkönen H; Stresing V; Bonnelye E; Green J; Mönkkönen J; Touraine JL; Clézardin P
    Cancer Res; 2011 Jul; 71(13):4562-72. PubMed ID: 21646473
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.